REG - Roquefort Theraptcs. - Commencement of Trading on US OTCQB Venture Market

Roquefort TherapeuticsAnnouncement

15/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220715:nRSO5622Sa&default-theme=true

RNS Number : 5622S  Roquefort Therapeutics PLC  15 July 2022

15 July 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Commencement of Trading on US OTCQB Venture Market

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, is pleased
to announce that trading in the Company's Ordinary Shares of one pence each
("Ordinary Shares") has commenced on the OTCQB Venture Market in the United
States. The Company's OTCQB shares have the ticker: ROQAF

 

There is no associated capital raise with this cross trading and Roquefort
Therapeutics's Ordinary Shares will continue to trade on its primary listing,
the Main Market of the London Stock Exchange, under the ticker ROQ.

 

Cross trading on the OTCQB market allows the Company to access one of the
world's largest investment markets to expand its reach into a broader pool of
investors. Roquefort Therapeutics shares will be available to US investors
during US working hours and priced in US dollars and thus has the potential to
enable greater liquidity in the Company's shares on the London Stock Exchange
by easing cross-border trading for potential US investors. Further information
about the OTCQB market can be found at:

 www.otcmarkets.com/learn/market-101
(http://www.otcmarkets.com/learn/market-101)

 

As a Foreign Private Issuer, Roquefort Therapeutics's onboarding to the OTC
Markets is based on satisfaction of the requirements for OTCQB as applicable
to international reporting companies including satisfaction of the criteria
for the exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting.
The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that
certain information made public or distributed under home market regulations
is made publicly available on the company's website or other electronic
information delivery system in English. Thus, the Company will have no
additional reporting obligations and incur minimal ongoing costs, compared to
traditional major exchanges.

 

As a verified market, the OTCQB offers transparent trading for companies that
have met a minimum bid price test, are current in their financial reporting
and have undergone an annual verification and management certification
process. The cross-trading facility is provided through OTC Markets Group
Inc., located in New York. OTC Markets operates the world's largest electronic
interdealer quotation system for US broker dealers and offers multiple media
channels to increase the visibility of OTC-listed companies. Online brokers
such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and
E-trade all offer OTCQB trades. US investors can find real-time quotes, market
information and access current company news and developments for Roquefort
Therapeutics at https://www.otcmarkets.com/stock/ROQAF/overview
(https://www.otcmarkets.com/stock/ROQAF/overview) .

 

Roquefort Therapeutics has appointed MCAP LLP as its OTCQB Sponsor.

 

Stephen West, Roquefort Therapeutics Executive Chairman, commented:

"Joining the OTCQB market provides Roquefort Therapeutics access to a
significant investment market, and with minimal ongoing costs associated and
no additional reporting requirements, is a positive step forward for the
Company. Having cross trading capabilities is important for the development of
Roquefort Therapeutics and we believe this listing will provide the Company
access to US investors, both institutional and retail, significantly
increasing our exposure and trading liquidity.  Our aim is to build a leading
biotech company focused on oncology drugs and we are pleased to be offering US
investors the opportunity to participate in our growth."

 

-Ends-

 

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is focused on developing first in class
Midkine inhibiting drugs for the treatment of cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific publications, Roquefort Therapeutics has identified the
potential to exploit the broad therapeutic potential of Midkine for a number
of clinical indications of significant unmet needs. Roquefort Therapeutics
holds an exclusive licence to the largest global IP portfolio on Midkine. The
Midkine blocking drug development markets have significant global market
potential (in the multi-billion dollars). Roquefort Therapeutics's
pre-clinical programme is currently underway with an initial focus on cancer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSRIMFTMTTBBLT